Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.

Join me as I recount my journey to Osama bin Laden’s compound in Pakistan. This video covers the unique route I took, the ...

In this video, the humorous side of dining at Olive Garden is explored through the lens of the waitstaff. It showcases the ...

This summary covers recent developments in health, including Novo Nordisk filing lawsuits against semaglutide compounders, ...

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

Advanced Micro Devices ( AMD -1.39%) upped its Q3 revenue guidance to $8.4 billion to $9 billion, and Q2's $7.7 billion ...

The popularity of Novo Nordisk's anti-diabetes and weight-loss treatments Ozempic and Wegovy had once made it a darling of ...

Danish pharma giant Novo Nordisk reports 32% rise in Q2 net profit to $4.1B, driven by strong sales of Ozempic and Wegovy ...

Novo Nordisk (NVO) stock was down pre-market after the company missed on top and bottom lines of second quarter earnings ...

The tech trade is proving resilient, even unstoppable, while the firms that gained by helping people lose weight are ...

OpenAI-backed start-up Chai Discovery has raised $70mn, valuing the group at about $550mn, as investors bet on the potential for artificial intelligence to speed up drug discovery and tackle disease.